Glizamide 30 Tablet contains Gliclazide IP 30mg, a sulfonylurea class antidiabetic agent used for controlling blood sugar levels in patients with type 2 diabetes. It stimulates insulin secretion from pancreatic beta cells, helping maintain glycemic control.
This tablet belongs to the diabetes care segment, offering an effective oral therapy for managing blood glucose in conjunction with diet and lifestyle adjustments. Its moderate dose is ideal for initiating therapy and for dose titration based on patient requirements.
Glizamide 30 Tablet is widely prescribed by endocrinologists, general physicians, hospitals, and clinics, making it a high-demand product for PCD pharma franchise and B2B distribution. Its proven efficacy and safety profile ensure patient adherence and repeat prescriptions.
For PCD pharma franchise and B2B partners, Glizamide 30 Tablet represents a profitable and high-demand opportunity. Its inclusion in antidiabetic portfolios, hospital and retail demand, and broad patient usage make it ideal for domestic distribution, export, and third-party manufacturing, ensuring sustainable business growth.